Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
regenxbio
Overview
REGENXBIO Inc. is a clinical-stage biotechnology company at the forefront of gene therapy innovation, specializing in the development and commercialization of adeno-associated virus (AAV) based therapies. Primarily focused on addressing severe genetic diseases with significant unmet medical needs, REGENXBIO utilizes its proprietary NAV Technology Platform™ to develop novel gene therapies. Their strategic focus lies in developing therapies internally and through strategic partnerships, positioning them as a key player in the rapidly expanding gene therapy market, aiming to either out-license assets or co-develop them with larger pharmaceutical entities to maximize market reach and commercial potential.
regenxbio's headcount breakdown by department
| Department | HeadCount |
|---|---|
Administrative | 4 |
Consulting | 1 |
Service | 3 |
Design | 0 |
Education | 0 |
Finance | 5 |
Management | 12 |
Hr | 3 |
Legal | 9 |
Marketing | 1 |
Medical | 29 |
Operations | 46 |
Department | 85 |
Product | 1 |
Management | 9 |
Estate | 0 |
Research | 59 |
Sales | 2 |
Technical | 16 |
Trades | 1 |
REGENXBIO's departmental structure strongly reflects its core identity as a research-intensive biotechnology company deeply invested in the development and clinical validation of novel gene therapies. The substantial allocation of personnel to 'Research' and 'Other Department' (which likely encompasses supporting scientific roles) underscores a commitment to cutting-edge innovation and the discovery of new therapeutic targets. The sizeable 'Operations' department suggests a significant investment in manufacturing capabilities, crucial for producing AAV vectors at scale for clinical trials and, eventually, commercialization. A robust 'Medical' department highlights the importance of clinical development, regulatory affairs, and medical affairs to navigate the complex path to market approval. The presence of a 'Technical' team, while not as large as other departments, indicates attention to process development, formulation, and analytical testing required for gene therapy manufacturing. The smaller teams in 'Sales' and 'Marketing' suggest a strategy of pursuing strategic partnerships for commercialization, rather than building a large internal salesforce at this stage. The notable investment in the 'Legal' department underscores the critical importance of intellectual property protection, licensing agreements, and navigating complex regulatory landscapes within the biotechnology sector. The department distribution is highly aligned with a business model centered around research, rigorous clinical development, and establishing efficient, scalable manufacturing processes, positioning REGENXBIO for both internal pipeline advancement and strategic partnerships to maximize the potential of its gene therapy platform.
regenxbio's employees by locations
Employee Count by Country
Total: 286 employees
REGENXBIO's geographic footprint is heavily concentrated in the United States, reflecting a strategic focus on leveraging the robust US biotechnology ecosystem for its core operations. The vast majority of employees are based in the US, facilitating access to key resources, talent, and regulatory expertise, particularly from the FDA. This domestic concentration allows REGENXBIO to efficiently manage its research, development, and clinical trial activities. The limited presence in the Netherlands and Saudi Arabia (one employee each) likely represents either preliminary stages of international collaboration, the location of specific research projects, or the establishment of initial footholds for future expansion. Given the capital-intensive and highly regulated nature of gene therapy development, the current strategy of a strong domestic base allows for optimal control and efficient resource allocation. As REGENXBIO's pipeline matures and therapies move closer to commercialization, a more diversified global presence may become strategically advantageous, either through direct operations or strategic partnerships to access international markets.
Want to stay ahead of regenxbio's org changes?
Get alerts when hiring spikes or teams shift focus
Track changes vs. competitors
Spot warm GTM signals early